Pfizer's Early 1990s Decision to Abandon Promising GLP-1 Therapy Development
Even the biggest future blockbuster drugs can be prematurely abandoned.
Read the full articleYou might also wanna read
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
Stronger safeguards are needed to ensure independent and transparent recommendations Glucagon-like peptide-1 (GLP-1) receptor agonists and r
bmj.com·27d ago
How new weight-loss drugs may offer hope for curbing addiction
Drugmakers are racing to develop ever newer versions of the GLP-1 drugs, and regulators around the world are approving them at an equally ra
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.
New GLP-1 Drug Promotes Weight Loss in Obesity
A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to an 11 percent reduction in body
Beyond the Step Change: What GLP-1s Solved - and What They Didn’t
GLP-1 therapies have redefined what obesity pharmacotherapy can achieve, but efficacy is no longer the only battleground.
GLP-1 Receptor Agonists Show Promise Against Obesity Related Cancer
The post GLP-1 Receptor Agonists Show Promise Against Obesity Related Cancer appeared first on European Medical Journal .
Comments
Sign in to join the conversation.
No comments yet. Be the first.